{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:46:34Z","timestamp":1790837194831,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,8,26]],"date-time":"2010-08-26T00:00:00Z","timestamp":1282780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2010,8,26]],"date-time":"2010-08-26T00:00:00Z","timestamp":1282780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s10637-010-9511-6","type":"journal-article","created":{"date-parts":[[2010,8,25]],"date-time":"2010-08-25T02:50:13Z","timestamp":1282704613000},"page":"273-281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers"],"prefix":"10.1007","volume":"30","author":[{"given":"Yazdi K.","family":"Pithavala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janessa","family":"Mount","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadayappan V.","family":"Rahavendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Selaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenad","family":"Sarapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen J.","family":"Klamerus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,8,26]]},"reference":[{"key":"9511_CR1","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","volume":"14","author":"DD Hu-Lowe","year":"2008","unstructured":"Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272\u20137283. doi:10.1158\/1078-0432.CCR-08-0652","journal-title":"Clin Cancer Res"},{"key":"9511_CR2","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","volume":"8","author":"O Rixe","year":"2007","unstructured":"Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8:975\u2013984. doi:10.1016\/S1470-2045(07)70285-1","journal-title":"Lancet Oncol"},{"key":"9511_CR3","doi-asserted-by":"crossref","first-page":"9006","DOI":"10.1200\/jco.2008.26.15_suppl.9006","volume":"26","author":"J Fruehauf","year":"2008","unstructured":"Fruehauf J, Lutzky J, McDermott D, Brown CK, Pithavala Y, Bycott P, Shalinsky D, Liau KF, Niethammer A, Rixe O (2008) Axitinib (AG-013736) in patients with metastatic melanoma: a phase II study. J Clin Oncol (Meeting Abstracts) 26: 9006.","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"9511_CR4","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1200\/JCO.2008.21.7034","volume":"27","author":"BI Rini","year":"2009","unstructured":"Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462\u20134468. doi:10.1200\/JCO.2008.21.7034","journal-title":"J Clin Oncol"},{"key":"9511_CR5","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1200\/JCO.2008.20.8355","volume":"27","author":"JH Schiller","year":"2009","unstructured":"Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J (2009) Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 27:3836\u20133841. doi:10.1200\/JCO.2008.20.8355","journal-title":"J Clin Oncol"},{"key":"9511_CR6","doi-asserted-by":"publisher","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","volume":"26","author":"EE Cohen","year":"2008","unstructured":"Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708\u20134713. doi:10.1200\/JCO.2007.15.9566","journal-title":"J Clin Oncol"},{"key":"9511_CR7","doi-asserted-by":"publisher","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","volume":"23","author":"HS Rugo","year":"2005","unstructured":"Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23:5474\u20135483","journal-title":"J Clin Oncol"},{"key":"9511_CR8","doi-asserted-by":"publisher","unstructured":"Pithavala YK, Tortorici M, Toh M, Garrett M, Hee B, Kuruganti U, Ni G, Klamerus KJ (2010) Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol 65: 563-570. doi:10.1007\/s00280-009-1065-y","DOI":"10.1007\/s00280-009-1065-y"},{"key":"#cr-split#-9511_CR9.1","unstructured":"Zientek M, Kang P, Jiang Y, Neul D, Friewald S, Smith BJ (2010) In vitro kinetic characterization of axitinib metabolism to estimate the clinical implications of genetic polymorphisms. International Society for the Study of Xenobiotics-Workshop on Genetic Polymorphisms in Drug Disposition"},{"key":"#cr-split#-9511_CR9.2","unstructured":"Indianapolis, IN, April 11-13, 2010"},{"key":"9511_CR10","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1124\/dmd.106.009738","volume":"34","author":"S Takeda","year":"2006","unstructured":"Takeda S, Kitajima Y, Ishii Y, Nishimura Y, Mackenzie PI, Oguri K, Yamada H (2006) Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Drug Metab Dispos 34:1277\u20131282","journal-title":"Drug Metab Dispos"},{"key":"9511_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00228-007-0396-z","volume":"64","author":"A Rakhit","year":"2008","unstructured":"Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 64:31\u201341. doi:10.1007\/s00228-007-0396-z","journal-title":"Eur J Clin Pharmacol"},{"key":"9511_CR12","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1038\/sj.clpt.6100048","volume":"81","author":"M Garrett","year":"2007","unstructured":"Garrett M, Houk BE, Myrand SP, Hee B, Mota J, Pithavala YK (2007) A population pharmacokinetic (PK) analysis to evaluate the potential effect of the UGT1A1*28 genotype on the PK of AG-013736, an anti-angiogenic agent. Clin Pharmacol Ther 81:S21\u2013S21","journal-title":"Clin Pharmacol Ther"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9511-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-010-9511-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10637-010-9511-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9511-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:07:27Z","timestamp":1678511247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-010-9511-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,26]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["9511"],"URL":"https:\/\/doi.org\/10.1007\/s10637-010-9511-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,26]]},"assertion":[{"value":"24 March 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}